Loading
AP
Albireo Pharma, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by PERCEPTIVE ADVISORS LLC, was filed 15 Sept 2020.
Albireo Pharma, Inc.: what insiders have been doing
Albireo Pharma, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). No insider at Albireo Pharma, Inc. has published a filing in the past twelve months. The most recent one dates from 3 March 2023.
The full history, which starts in 2016, counts 6 purchases against 123 sales.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
196
Thresholds
n/a
Buy Volume
€26M
6 ops. · all time
Sell Volume
€27M
123 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2021FY ended December 2021 · cache
Income statement
RevenueUS$34.9M
Gross profitUS$33.8M97% margin
Net income-US$29.3M-83.9% margin
Last declaration on 3 March 2023
Declarations196 total
56,278 sharesCommon StockSEC:0001209191-23-015092:0
22,242 sharesCommon StockSEC:0001209191-23-014769:0
13,739 sharesCommon StockSEC:0001209191-23-014786:0
33,094 sharesCommon StockSEC:0001209191-23-014778:0
3,296 sharesCommon StockSEC:0001209191-23-014741:0
3,656 sharesCommon StockSEC:0001209191-23-014753:0
35,524 sharesCommon StockSEC:0001209191-23-014736:0
5,543 sharesCommon StockSEC:0001209191-23-014763:0
55,000 shares0Common StockSEC:0001209191-23-005335:0
55,000 shares0Common StockSEC:0001209191-23-005337:0
55,000 shares0Common StockSEC:0001209191-23-005336:0
55,000 shares0Common StockSEC:0001209191-23-005332:0
55,000 shares0Common StockSEC:0001209191-23-005331:0
55,000 shares0Common StockSEC:0001209191-23-005333:0
195,000 shares0Common StockSEC:0001209191-23-005338:0
32,000 shares0Common StockSEC:0001209191-23-005334:0
32,000 shares0Common StockSEC:0001209191-23-004949:0
55,000 shares0Common StockSEC:0001209191-23-004946:0
55,000 shares0Common StockSEC:0001209191-23-004950:0
55,000 shares0Common StockSEC:0001209191-23-004951:0
55,000 shares0Common StockSEC:0001209191-23-004948:0
55,000 shares0Common StockSEC:0001209191-23-004952:0
195,000 shares0Common StockSEC:0001209191-23-004953:0
55,000 shares0Common StockSEC:0001209191-23-004947:0
102 shares@ US$43.802.4% of flowCommon StockSEC:0001209191-23-004459:0
25 of 196 declarations
About Albireo Pharma, Inc.
Albireo Pharma, Inc. (ticker: ALBO) was a U.S.-listed biopharmaceutical company that traded on the NASDAQ in the United States. The company focused on rare pediatric liver diseases, with a scientific and commercial strategy built around bile acid modulation and, more specifically, inhibition of the intestinal bile acid transporter (IBAT). Albireo was formed in 2008 through a spin-out from AstraZeneca, based on a portfolio of IBAT inhibitor assets, and its corporate headquarters were in Boston, Massachusetts. That origin and location placed the company squarely in the U.S. biotech ecosystem, close to one of the industry’s most active research and financing hubs.
From an operating standpoint, Albireo was essentially a specialist rare-disease developer rather than a diversified pharmaceutical group. Its lead asset was odevixibat, marketed as Bylvay, which became the company’s flagship product in cholestatic rare diseases such as progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome in certain markets. The commercial logic was straightforward: target severe orphan indications with high unmet medical need, where even modest clinical differentiation can support premium pricing and meaningful medical adoption. However, that model also implied concentration risk, with enterprise value heavily dependent on a narrow asset base, regulatory milestones, label expansions, and launch execution.
Read moreShow less
In competitive terms, Albireo occupied a niche position in the rare pediatric hepatology space. Its differentiation came from being one of the more focused players pursuing IBAT inhibition as a mechanism, rather than competing broadly across hepatology or gastroenterology. The company’s geographic footprint was initially centered in the United States, but like many orphan-drug developers, its commercial opportunity depended on international regulatory approvals and market access beyond the domestic market. For investors, the key question was always whether the company could convert clinical promise into sustainable global revenues across a limited number of ultra-rare diseases.
A major recent development was Albireo’s acquisition by BioMarin, which removed ALBO as an independent public equity story. That transaction is important context for any analysis of historical SEC Form 4 insider activity, because filings may still appear in the record even though the company’s standalone market status has changed. In other words, Albireo should be viewed today primarily as a legacy biotech asset and a case study in rare-disease M&A. For French, Belgian, and Swiss investors, ALBO is representative of a classic U.S. small-cap biotech profile: science-driven growth potential, heavy regulatory dependence, limited product diversification, and strategic value enhanced by acquisition interest in the rare-disease sector.
